METTL3 and ovarian dysfunction: CTX treatment upregulated the m6A writers METTL3, METTL14, ZC3H13 and KIAA1429, while downregulating the demethylase FTO and several m6A readers112, 113.These results indicate that m6A modification may act as a potential biomarker of ovarian dysfunction 112, 113.